Table of Contents Author Guidelines Submit a Manuscript
Journal of Analytical Methods in Chemistry
Volume 2012, Article ID 436349, 7 pages
http://dx.doi.org/10.1155/2012/436349
Research Article

High-Performance Liquid Chromatography Assay for Moxifloxacin in Brain Tissue and Plasma: Validation in a Pharmacokinetic Study in a Murine Model of Cerebral Listeriosis

1Laboratoire de Suivi Thérapeutique et de Contrôle des Médicaments, Service de Pharmacie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker-Enfants Malades, 75015 Paris, France
2Laboratoire de Listeria, Centre National de Référence des Listeria and World Health Organization Collaborating Centre for Foodborne Listeriosis, Institut Pasteur, 75015 Paris, France

Received 21 November 2011; Accepted 29 December 2011

Academic Editor: Adam Voelkel

Copyright © 2012 Renaud Respaud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. B. Balfour and L. R. Wiseman, “Moxifloxacin,” Drugs, vol. 57, no. 3, pp. 363–374, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. “The Merck index,” p. 1125, 2001.
  3. J. M. Farber and P. I. Peterkin, “Listeria monocytogenes, a food-borne pathogen,” Microbiological Reviews, vol. 55, no. 3, pp. 476–511, 1991. View at Google Scholar · View at Scopus
  4. V. Goulet and P. Marchetti, “Listeriosis in 225 non-pregnant patients in 1992: clinical aspects and outcome in relation to predisposing conditions,” Scandinavian Journal of Infectious Diseases, vol. 28, no. 4, pp. 367–374, 1996. View at Google Scholar · View at Scopus
  5. S. Grayo, O. Join-Lambert, M. C. Desroches, and A. Le Monnier, “Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 5, pp. 1697–1702, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Hof, “An update on the medical management of listeriosis,” Expert Opinion on Pharmacotherapy, vol. 5, no. 8, pp. 1727–1735, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Grayo, M. C. Lott-Desroches, O. Dussurget et al., “Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 9, pp. 3210–3215, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Scortti, L. Lacharme-Lora, M. Wagner, I. Chico-Calero, P. Losito, and J. A. Vázquez-Boland, “Coexpression of virulence and fosfomycin susceptibility in Listeria: molecular basis of an antimicrobial in vitro-in vivo paradox,” Nature Medicine, vol. 12, no. 5, pp. 515–517, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. B. B. Ba, R. Etienne, D. Ducint, C. Quentin, and M. C. Saux, “Determination of moxifloxacin in growth media by high-performance liquid chromatography,” Journal of Chromatography B, vol. 754, no. 1, pp. 107–112, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Laban-Djurdjević, M. Jelikić-Stankov, and P. Djurdjević, “Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma,” Journal of Chromatography B, vol. 844, no. 1, pp. 104–111, 2006. View at Publisher · View at Google Scholar
  11. H. Liang, M. B. Kays, and K. M. Sowinski, “Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma,” Journal of Chromatography B, vol. 772, no. 1, pp. 53–63, 2002. View at Publisher · View at Google Scholar
  12. H. M. Siefert, A. Domdey-Bette, K. Henninger, F. Hucke, C. Kohlsdorfer, and H. H. Stass, “Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species,” Journal of Antimicrobial Chemotherapy, vol. 43, supplement B, pp. 69–76, 1999. View at Publisher · View at Google Scholar
  13. K. Kanellakopoulou, A. Pagoulatou, K. Stroumpoulis et al., “Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 6, pp. 1328–1331, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Rodriguez-Cerrato, C. C. McCoig, I. C. Michelow et al., “Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 11, pp. 3092–3097, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. ICH, “Validation of analytical procedures: methodology. Guideline 2QB,” Federal Register, vol. 62, no. 96, pp. 27463–27467, 1997. View at Google Scholar
  16. ICH, “Note for guidance on validation of analytical methods: definitions and terminology (Q2A),” in Proceedings of the International Conference of Harmonisation, 1994.
  17. P. Glaser, L. Frangeul, C. Buchrieser et al., “Comparative genomics of Listeria species,” Science, vol. 294, no. 5543, pp. 849–852, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. A. K. Hemanth Kumar and G. Ramachandran, “Simple and rapid liquid chromatography method for determination of moxifloxacin in plasma,” Journal of Chromatography B, vol. 877, no. 11-12, pp. 1205–1208, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Tatar Ulu, “High-performance liquid chromatography assay for moxifloxacin: pharmacokinetics in human plasma,” Journal of Pharmaceutical and Biomedical Analysis, vol. 43, no. 1, pp. 320–324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Østergaard, T. K. Sørensen, J. D. Knudsen, and N. Frimodt-Møller, “Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 7, pp. 1706–1712, 1998. View at Google Scholar
  21. R. Wise, J. M. Andrews, G. Marshall, and G. Hartman, “Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 6, pp. 1508–1510, 1999. View at Google Scholar · View at Scopus
  22. M. B. Kays and G. A. Denys, “Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana,” Diagnostic Microbiology and Infectious Disease, vol. 40, no. 4, pp. 193–198, 2001. View at Publisher · View at Google Scholar
  23. M. J. Montgomery, P. M. Beringer, A. Aminimanizani et al., “Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 12, pp. 3468–3473, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. J. W. C. Alffenaar, R. Van Altena, H. J. Bökkerink et al., “Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis,” Clinical Infectious Diseases, vol. 49, no. 7, pp. 1080–1082, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. D. Chaudhuri, “Blood brain barrier and infection,” Medical Science Monitor, vol. 6, no. 6, pp. 1213–1222, 2000. View at Google Scholar · View at Scopus